Puma Biotechnology (PBYI) Share-based Compensation (2012 - 2026)

Puma Biotechnology's Share-based Compensation history runs 15 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• Quarterly Share-based Compensation fell 16.09% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 78.46% YoY) and the FY2025 annual result came in at $6.9 million, down 15.78% from the prior year.
• Share-based Compensation was $1.7 million for Q1 2026 at Puma Biotechnology, up from $1.6 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.2 million in Q2 2022 and bottomed at $700000.0 in Q3 2025.
• A 5-year average of $2.2 million and a median of $2.4 million in 2024 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 117.78% in 2022, while the deepest fall reached 82.35% in 2022.
• Puma Biotechnology's Share-based Compensation stood at $2.6 million in 2022, then declined by 7.46% to $2.4 million in 2023, then decreased by 27.96% to $1.8 million in 2024, then dropped by 7.71% to $1.6 million in 2025, then gained by 5.13% to $1.7 million in 2026.
• Business Quant data shows PBYI's Share-based Compensation at $1.7 million in Q1 2026, $1.6 million in Q4 2025, and $700000.0 in Q3 2025.